US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Abeona Therapeutics Inc. - Common Stock
(NQ:
ABEO
)
4.400
-0.070 (-1.57%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abeona Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
September 18, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
September 16, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
September 08, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
September 02, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 01, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
August 13, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
August 06, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
August 04, 2026
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
July 21, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
May 13, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
May 11, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Date of First Quarter Financial Results
May 04, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
April 07, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
April 02, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
March 17, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
March 09, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
March 03, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
